1. Efficacy and Safety of Cariprazine in Acute Management of Psychiatric Disorders: a Meta-Analysis of Randomized Controlled Trials
- Author
-
Christine Reynaert, Brice Lepièce, Nicolas Zdanowicz, Thomas Dubois, and Denis Jacques
- Subjects
medicine.medical_specialty ,medicine.drug_class ,Atypical antipsychotic ,Cariprazine ,Piperazines ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,law ,mental disorders ,medicine ,Humans ,cariprazine ,schizophrenia ,bipolar disorders ,major depressive disorder ,psychiatric disorders ,Psychiatry ,Randomized Controlled Trials as Topic ,Positive and Negative Syndrome Scale ,business.industry ,Mental Disorders ,Hamilton Rating Scale for Depression ,General Medicine ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,Treatment Outcome ,chemistry ,Montgomery–Åsberg Depression Rating Scale ,Major depressive disorder ,medicine.symptom ,business ,Mania ,Antipsychotic Agents - Abstract
Background: Cariprazine is a new atypical antipsychotic drug approved for the treatment of schizophrenia and bipolar disorders. Methods: we searched the published randomized controlled-trials (RCT) to review cariprazine efficacy and tolerability using the databases (PubMed, EUDRACT, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials) for cariprazine role in managing the following psychiatric conditions (schizophrenia, bipolar mania, bipolar depression and major depressive disorder). A meta-analysis was conducted using the identified 13 clinical trials to assess efficacy using with the outcomes: positive and negative syndrome scale (PANSS), clinical global impressions - severity of Illness (CGI-S), young mania rating scales (YMRS), Montgomery Asberg depression rating scale (MADRS) and Hamilton rating scale for depression (HAM-D). The risk of discontinuation due to adverse effects and common side effects were examined. Results: The mean difference in change from baseline for PANSS was -6.23 (95% Confidence Interval (CI) -7.18, -5.28) favoring cariprazine treatment (p
- Published
- 2020